High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to determine whether doses of 15 mCi/kg and 18 mCi/kg of 131I-MIBG are
tolerable when given with irinotecan/vincristine on a one week schedule to children and young
adults with high-risk refractory/relapsed neuroblastoma.